Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives
Primary cutaneous B-cell lymphomas are rare entities that develop primarily in the skin. They constitute a heterogeneous group that represents around a quarter of primary cutaneous lymphomas. The 2018 update of the World Health Organization-European Organization for Research and Treatment of Cancer...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-06-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/12/6/1497 |
| _version_ | 1797565859059728384 |
|---|---|
| author | Maëlle Dumont Maxime Battistella Caroline Ram-Wolff Martine Bagot Adèle de Masson |
| author_facet | Maëlle Dumont Maxime Battistella Caroline Ram-Wolff Martine Bagot Adèle de Masson |
| author_sort | Maëlle Dumont |
| collection | DOAJ |
| description | Primary cutaneous B-cell lymphomas are rare entities that develop primarily in the skin. They constitute a heterogeneous group that represents around a quarter of primary cutaneous lymphomas. The 2018 update of the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification differentiates primary cutaneous marginal zone lymphoma and primary cutaneous follicle center lymphoma with an indolent course from primary cutaneous diffuse large B-cell lymphoma, leg type with an aggressive behavior. The broad spectrum of clinical presentations and the disease course marked by frequent relapses are diagnostic and therapeutic challenges. The classification of these diseases has been refined in recent years, which allows to better define their immunopathogenesis and specific management. In the present article, we review the main clinico-biological characteristics and the current therapeutic options of these three main subsets. Based on the recent therapeutic advances in nodal B-cell lymphomas, we focus on the development of novel treatment options applicable to primary cutaneous B-cell lymphomas, including targeted therapies, combination treatments and immunotherapeutic approaches, and cover basic, translational and clinical aspects aiming to improve the treatment of cutaneous B-cell lymphomas. |
| first_indexed | 2024-03-10T19:17:58Z |
| format | Article |
| id | doaj.art-740290a64161413aa8e22339b9c32fdc |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T19:17:58Z |
| publishDate | 2020-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-740290a64161413aa8e22339b9c32fdc2023-11-20T03:11:54ZengMDPI AGCancers2072-66942020-06-01126149710.3390/cancers12061497Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and PerspectivesMaëlle Dumont0Maxime Battistella1Caroline Ram-Wolff2Martine Bagot3Adèle de Masson4Department of Dermatology, APHP, Saint-Louis Hospital, F-75010 Paris, FranceINSERM U976, Human Immunology, Pathophysiology and Immunotherapy, Institut de Recherche Saint-Louis, F-75010 Paris, FranceDepartment of Dermatology, APHP, Saint-Louis Hospital, F-75010 Paris, FranceDepartment of Dermatology, APHP, Saint-Louis Hospital, F-75010 Paris, FranceDepartment of Dermatology, APHP, Saint-Louis Hospital, F-75010 Paris, FrancePrimary cutaneous B-cell lymphomas are rare entities that develop primarily in the skin. They constitute a heterogeneous group that represents around a quarter of primary cutaneous lymphomas. The 2018 update of the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification differentiates primary cutaneous marginal zone lymphoma and primary cutaneous follicle center lymphoma with an indolent course from primary cutaneous diffuse large B-cell lymphoma, leg type with an aggressive behavior. The broad spectrum of clinical presentations and the disease course marked by frequent relapses are diagnostic and therapeutic challenges. The classification of these diseases has been refined in recent years, which allows to better define their immunopathogenesis and specific management. In the present article, we review the main clinico-biological characteristics and the current therapeutic options of these three main subsets. Based on the recent therapeutic advances in nodal B-cell lymphomas, we focus on the development of novel treatment options applicable to primary cutaneous B-cell lymphomas, including targeted therapies, combination treatments and immunotherapeutic approaches, and cover basic, translational and clinical aspects aiming to improve the treatment of cutaneous B-cell lymphomas.https://www.mdpi.com/2072-6694/12/6/1497cutaneous B-cell lymphomaslymphoid malignanciesB-cellslymphocytesskinlymphomas |
| spellingShingle | Maëlle Dumont Maxime Battistella Caroline Ram-Wolff Martine Bagot Adèle de Masson Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives Cancers cutaneous B-cell lymphomas lymphoid malignancies B-cells lymphocytes skin lymphomas |
| title | Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives |
| title_full | Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives |
| title_fullStr | Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives |
| title_full_unstemmed | Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives |
| title_short | Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives |
| title_sort | diagnosis and treatment of primary cutaneous b cell lymphomas state of the art and perspectives |
| topic | cutaneous B-cell lymphomas lymphoid malignancies B-cells lymphocytes skin lymphomas |
| url | https://www.mdpi.com/2072-6694/12/6/1497 |
| work_keys_str_mv | AT maelledumont diagnosisandtreatmentofprimarycutaneousbcelllymphomasstateoftheartandperspectives AT maximebattistella diagnosisandtreatmentofprimarycutaneousbcelllymphomasstateoftheartandperspectives AT carolineramwolff diagnosisandtreatmentofprimarycutaneousbcelllymphomasstateoftheartandperspectives AT martinebagot diagnosisandtreatmentofprimarycutaneousbcelllymphomasstateoftheartandperspectives AT adeledemasson diagnosisandtreatmentofprimarycutaneousbcelllymphomasstateoftheartandperspectives |